AbbVie in charts: Revenues from Humira -50.6%, Skyrizi +70.6%, Rinvoq +57.2% Y/Y Posted on April 25, 2025 by wpadmin More on AbbVie AbbVie: Thriving Beyond Humira’s Patent Cliff (Upgrade) AbbVie: Margin Expansion Potential Can Support Elevated P/E AbbVie Vs. Sanofi: Which Is The Better Investment Right Now AbbVie Non-GAAP EPS of $2.46 beats by $0.06, revenue of $13.34B beats by $420M AbbVie Q1 2025 Earnings Preview
